How are energy investors positioned?
Jennifer Berres, Senior Vice President and Chief Human Resources Officer at HCA Healthcare Inc. (NYSE:HCA), a prominent healthcare provider with a market capitalization of $78.6 billion and annual revenue of $70.6 billion, recently sold a substantial portion of her shares in the company, according to a Form 4 filing with the Securities and Exchange Commission. According to InvestingPro analysis, HCA maintains strong financial health with robust profitability metrics. On February 14, Berres sold 9,533 shares of HCA common stock, generating approximately $3.08 million. The shares were sold at prices ranging from $322.31 to $322.96 each. Trading at a P/E ratio of 14.2x and showing strong fundamentals, InvestingPro analysis suggests the stock is currently trading below its Fair Value, with 12+ additional exclusive insights available to subscribers.
In a separate transaction on February 13, Berres acquired 1,588 shares through the vesting of performance share units, which were granted based on the company’s earnings performance from 2022 to 2024. Additionally, Berres disposed of 407 shares at a price of $321.92 per share to cover tax obligations related to the vesting of these units.
Following these transactions, Berres holds a total of 15,412 shares of HCA common stock.
In other recent news, HCA Healthcare Inc. has experienced a flurry of activity. The healthcare provider announced a senior notes offering, planned by its subsidiary, HCA Inc., with terms to be determined at the time of pricing. Joint book-running managers for the offering include BofA Securities, Inc., Barclays (LON:BARC) Capital Inc., Citigroup (NYSE:C) Global Markets Inc., J.P. Morgan Securities LLC, Mizuho (NYSE:MFG) Securities USA LLC, and Wells Fargo (NYSE:WFC) Securities, LLC.
Alongside this, several financial firms have offered their perspectives on HCA Healthcare’s performance. Cantor Fitzgerald maintained an Overweight rating on HCA’s stock with a $405 price target, expressing confidence in the company’s projected EBITDA for 2025. Similarly, Mizuho Securities reiterated an Outperform rating on HCA Healthcare, holding steady with a $425 target.
Bernstein SocGen Group adjusted its price target for HCA Healthcare, raising it to $342 from $331, while retaining a Market Perform rating. This followed HCA’s fourth-quarter results for 2024, where the company reported an Adjusted EBITDA of $3,712 million and revenues of $18.3 billion.
TD Cowen, on the other hand, maintained a Buy rating on HCA Healthcare but reduced the price target from $440 to $377. This adjustment came after HCA’s fourth-quarter 2024 financial report, which showed a modest outperformance in revenue and EBITDA.
These developments offer insights into the recent happenings surrounding HCA Healthcare, providing a snapshot of the company’s financial journey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.